Mass Tort brief
Geopolitical Conflict Crosses into US Civil Litigation
Teva Pharmaceutical asks a US federal court to hide its Israeli parentage, fearing Gaza war sentiment could bias generic pricing jurors against the firm.
Signalpoint TeamBrief
Mass Tort
Teva is trying to strip its national identity from a US courtroom — setting up a benchmark for how global firms shield jury verdicts from foreign war sentiment.
BackgroundTeva's US subsidiary faces multi-district antitrust litigation alleging an industry-wide conspiracy to fix prices on generic medications. The bellwether trial scheduled for September 15 is the first major test case in a generic drug pricing probe that has stretched over a decade.
Points
- Teva argued in court filings that references to its Israeli parent company are legally irrelevant to generic drug pricing and present severe risks of unfair jury prejudice.
- Plaintiff Humana claims Teva colluded with competitors to artificially inflate generic drug prices, seeking hundreds of millions of dollars in damages for overcharges.
- The pre-trial motion highlights how international corporate defendants are attempting to insulate US civil trials from foreign policy fallout as public sentiment turns hostile.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
Or read free in the app